Article
Cell Biology
Nusrat Jahan, Catherine Jones, Rakhshanda Layeequr Rahman
Summary: Breast cancer is a common malignancy among women worldwide, and chemoprevention using antiestrogen therapy is an effective method of prevention. However, there is a lack of formal risk assessment and discussion of prevention options, potentially due to various contributing factors.
MOLECULAR AND CELLULAR ENDOCRINOLOGY
(2021)
Article
Cell Biology
Fahmida Rasha, Monica Sharma, Kevin Pruitt
Summary: The most common subtype of BC is characterized by ER expression, with treatment typically involving suppression of estrogen production or hindering estrogen binding to its receptors. Despite the benefits of endocrine therapy, overcoming resistance driven by complex changes in the tumor microenvironment remains a clinical challenge, highlighting the need for further investigation into ER modulation mechanisms.
MOLECULAR AND CELLULAR ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Sheng-Fan Wang, Yi-Sheng Lin, Wan-Yu Yeh, Yuh-Lih Chang, Chern-En Chiang, Chen-Huan Chen, Ling-Ming Tseng, Hsin-Chen Lee, Chun-Yu Liu, Hao-Min Cheng
Summary: This study summarizes the clinical effects of antiresorptive agents in patients with early breast cancer receiving endocrine therapy. The results show that antiresorptive agents have significant clinical benefits on disease recurrence and locoregional recurrence in these patients. However, there is a potential risk of osteonecrosis of the jaw with the use of these agents.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Oncology
Inga Bekes, Jens Huober
Summary: Seventy percent of breast cancer subtypes are hormone receptor-positive, and adjuvant endocrine therapy is crucial for these patients. Extending adjuvant endocrine therapy beyond 5 years has been shown to reduce the risk of late recurrence, but the optimal duration is still debated. Newer data suggest only marginal benefits beyond 7 to 10 years, and longer duration may result in more side effects. Therefore, it is important to select patients who qualify for extended therapy based on genomic tests and risk assessment.
Review
Cell Biology
Fiona H. Zhou, Teesha Downton, Allegra Freelander, Joshua Hurwitz, C. Elizabeth Caldon, Elgene Lim
Summary: CDK4/6 inhibitors have revolutionized the treatment of ER+ breast cancer and are the standard first-line therapy. However, resistance to these inhibitors is a challenge and there is a need to understand the mechanisms of resistance to guide subsequent treatment decisions.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Oncology
Yuxin Xie, Libo Yang, Yanqi Wu, Hong Zheng, Qiheng Gou
Summary: The study found that AI/T + AI combination endocrine therapy may be a reasonable treatment option for ER-low positive breast cancer patients, and treatment duration of more than 3 years is associated with better disease-free survival.
Article
Oncology
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Summary: The study evaluated the efficacy and safety of sapanisertib plus exemestane or fulvestrant in treating advanced/metastatic hormone receptor-positive breast cancer, showing certain clinical benefit for patients. The treatment demonstrated different efficacy in patients previously sensitive or resistant to exemestane.
CLINICAL CANCER RESEARCH
(2021)
Article
Cell Biology
Nahla M. Badr, David Spooner, Jane Steven, Andrea Stevens, Abeer M. Shaaban
Summary: This study investigated the effect of NAET on tumour type, grade, and molecular profile in breast cancer patients. Significant changes were observed, including complete pathological response in some cases, central scarring in almost half of the tumours post-treatment, and downgrading of tumour grade in one-third of cases. The study suggests a histological method for assessing residual carcinoma after NAET and recommends repeat ER/PR/HER2 testing for management and prognosis.
Review
Endocrinology & Metabolism
Esmael Besufikad Belachew, Dareskedar Tsehay Sewasew
Summary: The estrogen receptor is crucial in the treatment of estrogen receptor-positive breast cancer, with endocrine resistance posing a challenge. Combining drugs that target different signaling pathways and coregulatory proteins with endocrine therapy may offer a novel therapeutic approach to combat endocrine resistance.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Anette H. Skjervold, Marit Valla, Anna M. Bofin
Summary: In this study, we examined the associations between levels of ER expression and tumour characteristics and prognosis in three large cohorts of BC patients. The results showed that ER Low Positive tumours were mainly found in Luminal B (HER2+) subtype and grade 3 tumours. The risk of death from BC was lower in ER Low Positive and ER ≥ 10% compared to ER-negative cases. Patients diagnosed in 1995 or later with ER Low Positive BCs had smaller, lower-grade tumours with lower proliferation status and similar prognosis compared to those with ER ≥ 10% tumours.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Biochemistry & Molecular Biology
Seok-Hoon Jang, Se Hyun Paek, Jong-Kyu Kim, Je Kyung Seong, Woosung Lim
Summary: Hormone receptor-positive breast cancer cells rely on estrogen and its receptor, but resistance to endocrine therapy is common. By testing different culture conditions, researchers discovered that T47D cells respond well to estrogen under low cell density and medium replacement, which reduces the effectiveness of endocrine therapy. These findings provide new insights into endocrine therapy resistance and offer a new experimental model for future studies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Jooyoung Oh, Hye Sun Lee, Soyoung Jeon, Dooreh Kim, Jeong-Ho Seok, Woo-Chan Park, Jae-Jin Kim, Chang Ik Yoon
Summary: This study, using a nationwide population-based cohort, found no evidence that endocrine treatment increases the risk of depression in breast cancer patients.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Oncology
Johanna E. Poterala, Kari B. Wisinski
Summary: A shorter course of endocrine therapy may be reasonable for breast cancer patients with low estrogen receptor expression, but further validation is needed.
Article
Oncology
Ho Tsoi, Johann Lok, Ellen P. S. Man, Cheuk-Nam Cheng, Man-Hong Leung, Chan-Ping You, Sum-Yin Chan, Wing-Lok Chan, Ui-Soon Khoo
Summary: This study revealed that overexpression of a novel splice variant BQ323636.1 is associated with resistance to the non-steroidal aromatase inhibitor anastrozole in ER+ post-menopausal breast cancer. Mechanistic studies showed that BQ overexpression enhances androgen receptor (AR) activity, leading to hyper-activation of AR signaling and increased cell proliferation. Targeting AR can overcome anastrozole resistance in breast cancer with BQ overexpression. Clinical study also demonstrated that high nuclear expression of both BQ and AR is significantly associated with poor survival in non-steroidal aromatase inhibitor-treated ER+ breast cancer patients.
JOURNAL OF PATHOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Lea Clusan, Francois Ferriere, Gilles Flouriot, Farzad Pakdel
Summary: Breast cancer, the most common and deadliest cancer among women worldwide, is closely associated with estrogen signaling. Hormone therapy using antiestrogens is the standard treatment, but resistance inevitably occurs through various biological mechanisms. Understanding the estrogen pathway is crucial for the development of new therapies for hormone-dependent breast cancer. This mini-review summarizes the current literature on estrogen receptors in breast cancer, including their signalization, mechanisms of action, and clinical implications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Nikiana Simigdala, Sunil Pancholi, Ricardo Ribas, Elizabeth Folkerd, Gianmaria Liccardi, Joanna Nikitorowicz-Buniak, Stephen R. Johnston, Mitch Dowsett, Lesley-Ann Martin
BRITISH JOURNAL OF CANCER
(2018)
Article
Oncology
Xiaoling Puyang, Craig Furman, Guo Zhu Zheng, Zhenhua J. Wu, Deepti Banka, Kiran Aithal, Sergei Agoulnik, David M. Bolduc, Silvia Buonamici, Benjamin Caleb, Subhasree Das, Sean Eckley, Peter Fekkes, Ming-Hong Hao, Andrew Hart, Rene Houtman, Sean Irwin, Jaya J. Joshi, Craig Karr, Amy Kim, Namita Kumar, Pavan Kumar, Galina Kuznetsov, Weidong G. Lai, Nicholas Larsen, Crystal Mackenzie, Lesley-Ann Martin, Diana Melchers, Alyssa Moriarty, Tuong-Vi Nguyen, John Norris, Morgan O'Shea, Sunil Pancholi, Sudeep Prajapati, Sujatha Rajagopalan, Dominic J. Reynolds, Victoria Rimkunas, Nathalie Rioux, Ricardo Ribas, Amy Siu, Sasirekha Sivakumar, Vanitha Subramanian, Michael Thomas, Frederic H. Vaillancourt, John Wang, Suzanne Wardell, Michael J. Wick, Shihua Yao, Lihua Yu, Markus Warmuth, Peter G. Smith, Ping Zhu, Manav Korpal
Article
Oncology
Aziz Aiderus, Michael A. Black, Anita K. Dunbier
Article
Biochemistry & Molecular Biology
Sam A. Jamieson, Zheng Ruan, Abigail E. Burgess, Jack R. Curry, Hamish D. Mcmilan, Jodi L. Brewster, Anita K. Dunbier, Alison D. Axtman, Natarajan Kannan, Peter D. Mace
Article
Biochemistry & Molecular Biology
Georgina P. Sava, Hailing Fan, Rosemary A. Fisher, Sabrina Lusvarghi, Sunil Pancholi, Suresh Ambudkar, Lesley-Ann Martin, R. Charles Coombes, Lakjaya Buluwela, Simak Ali
Article
Cell Biology
Kimberly J. Cocce, Jeff S. Jasper, Taylor K. Desautels, Logan Everett, Suzanne Wardell, Thomas Westerling, Robert Baldi, Tricia M. Wright, Kendall Tavares, Alex Yllanes, Yeeun Bae, Jeremy T. Blitzer, Craig Logsdon, Daniel P. Rakiec, David A. Ruddy, Tiancong Jiang, Gloria Broadwater, Terry Hyslop, Allison Hall, Muriel Leine, Linda Phung, Geoffrey L. Greene, Lesley-Ann Martin, Sunil Pancholi, Mitch Dowsett, Simone Detre, Jeffrey R. Marks, Gregory E. Crawford, Myles Brown, John D. Norris, Ching-yi Chang, Donald P. McDonnell
Article
Pathology
Andre Franken, Ellen Honisch, Florian Reinhardt, Franziska Meier-Stiegen, Liwen Yang, Sandra Jaschinski, Irene Esposito, Barbara Alberter, Bernhard Polzer, Hanna Huebner, Peter A. Fasching, Sunil Pancholi, Lesley-Ann Martin, Eugen Ruckhaeberle, Fabienne Schochter, Marie Tzschaschel, Andreas D. Hartkopf, Volkmar Mueller, Dieter Niederacher, Tanja Fehm, Hans Neubauer
JOURNAL OF MOLECULAR DIAGNOSTICS
(2020)
Article
Biochemistry & Molecular Biology
Sunil Pancholi, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Joanna Nikitorowicz-Buniak, Anna Ressa, Qiong Gao, Mariana Ferreira Leal, Amandeep Bhamra, Allan Thornhill, Ludivine Morisset, Elodie Montaudon, Laura Sourd, Martin Fitzpatrick, Maarten Altelaar, Stephen R. Johnston, Elisabetta Marangoni, Mitch Dowsett, Lesley-Ann Martin
Article
Multidisciplinary Sciences
Elodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, Ludivine Morisset, Rania El Botty, Lea Huguet, Ahmed Dahmani, Pierre Painsec, Fariba Nemati, Sophie Vacher, Walid Chemlali, Julien Masliah-Planchon, Sophie Chateau-Joubert, Camilla Rega, Mariana Ferreira Leal, Nikiana Simigdala, Sunil Pancholi, Ricardo Ribas, Andre Nicolas, Didier Meseure, Anne Vincent-Salomon, Cecile Reyes, Audrey Rapinat, David Gentien, Thibaut Larcher, Mylene Bohec, Sylvain Baulande, Virginie Bernard, Didier Decaudin, Florence Coussy, Muriel Le Romancer, Guillaume Dutertre, Zakia Tariq, Paul Cottu, Keltouma Driouch, Ivan Bieche, Lesley-Ann Martin, Elisabetta Marangoni
NATURE COMMUNICATIONS
(2020)
Article
Oncology
Barrie Peck, Philip Bland, Ioanna Mavrommati, Gareth Muirhead, Hannah Cottom, Patty T. Wai, Sarah L. Maguire, Holly E. Barker, Eamonn Morrison, Divya Kriplani, Lu Yu, Amy Gibson, Giulia Falgari, Keith Brennan, Gillian Farnie, Richard Buus, Rebecca Marlow, Daniela Novo, Eleanor Knight, Naomi Guppy, Daniela Kolarevic, Snezana Susnjar, Natasa Medic Milijic, Kalnisha Naidoo, Patrycja Gazinska, Ioannis Roxanis, Sunil Pancholi, Lesley-Ann Martin, Erle M. Holgersen, Maggie C. U. Cheang, Farzana Noor, Sophie Postel-Vinay, Gerard Quinn, Simon McDade, Lukas Krasny, Paul Huang, Frances Daley, Fredrik Wallberg, Jyoti S. Choudhary, Syed Haider, Andrew N. Tutt, Rachael Natrajan
Summary: This study highlights the identification of CREBBP as a novel driver in aggressive TNBC, with associated genetic vulnerability in tumor cells with alterations in CREBBP, and provides a preclinical rationale for assessing CREBBP alterations as a biomarker of CDK4/6 inhibitor response in a new patient population. Targeting CREBBP alterations with clinical CDK4/6 inhibitors selectively impairs growth in spheroids, cell line xenografts, and patient-derived models from multiple tumor types.
Article
Oncology
Sunil Pancholi, Nikiana Simigdala, Ricardo Ribas, Eugene Schuster, Mariana Ferreira Leal, Joanna Nikitorowicz-Buniak, Camilla Rega, Teeru Bihani, Hitisha Patel, Stephen R. Johnston, Mitch Dowsett, Lesley-Ann Martin
Summary: This study found that the novel SERD drug elacestrant has potential therapeutic effects on breast cancer, showing activity in patients with ESR1 mutations and responding to acquired resistance to fulvestrant. Elacestrant has a similar impact on estrogen receptor activity, cell proliferation, and transcription as fulvestrant. Additionally, combining elacestrant with CDK4/6 inhibitors enhances the anti-proliferative effect.
Correction
Oncology
Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Gao, Stephen R. Johnston, Mitch Dowsett, Sabina C. Cosulich, Elisabetta Marangoni, Lesley-Ann Martin
BREAST CANCER RESEARCH
(2020)
Article
Oncology
Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Gao, Stephen R. Johnston, Mitch Dowsett, Sabina C. Cosulich, Elisabetta Maragoni, Lesley-Ann Martin
BREAST CANCER RESEARCH
(2019)
Article
Oncology
Ricardo Ribas, Sunil Pancholi, Aradhana Rani, Eugene Schuster, Stephanie K. Guest, Joanna Nikitorowicz-Buniak, Nikiana Simigdala, Allan Thornhill, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Mitch Dowsett, Stephen R. Johnston, Lesley-Ann Martin
BREAST CANCER RESEARCH
(2018)
Meeting Abstract
Oncology
Sunil Pancholi, Joanna Nikitorowicz-Buniak, Ricardo Ribas, Nikiana Simigdala, Fiona Garner, Teeru Bihani, Stephen R. Johnston, Mitch Dowsett, Lesley-Ann Martin
Article
Biochemistry & Molecular Biology
Olexander M. Semenenko, Victoria V. Lipson, Alina O. Sadchenko, Olga V. Vashchenko, Natalia A. Kasian, Liliia Sviechnikova, Longin M. Lisetski, Mykola L. Babak, Volodymyr M. Vakula, Oleksandr Borysov, Yuliia Holota, Sergey O. Zozulya, Petro O. Borysko, Olexander Mazepa
Summary: An efficient protocol for the synthesis of novel methotrexate-betulonic acid hybrids has been developed and their structures and properties have been fully established. The hybrids showed inferior interactions with artificial lipid membranes, possibly due to their increasing lipophilicity.
Article
Biochemistry & Molecular Biology
Mohadese Yaghoobi Anzabi, Piotr Cmoch, Roman Luboradzki, Zbigniew Pakulski
Summary: Friedelin and 3-acetoxyfriedel-3-en-2-one, known as friedelane triterpenoids, have been isolated from cork smoker wash solids and used as starting materials for the synthesis of new friedelane derivatives. Reduction reactions result in the formation of friedelinol and epi-cerin derivatives.
Article
Biochemistry & Molecular Biology
Detlef Thieme, Aniko Krumbholz, Martin Bidlingmaier, Christoph Geffert, Annika Hameder, Andreas Stoever, Matthias Graw, Annekathrin M. Keiler
Summary: Ethanol can affect testosterone metabolism and potentially influence steroid biosynthesis and blood steroid profiles. The study emphasizes the importance of sufficient time interval from food and ethanol intake during blood sampling, particularly for diagnostics in doping control.
Article
Biochemistry & Molecular Biology
Masanobu Murao, Tetsuo Imano, Yoshinobu Sato, Masaaki Nakajima
Article
Biochemistry & Molecular Biology
Jingyuan Wang, Ye Feng, Brian Liu, Wen Xie
Summary: Sulfation and desulfation of steroids are opposing processes that regulate steroid homeostasis and are involved in steroid-related diseases. Cytosolic sulfotransferase and steroid sulfatase modify and regulate steroids to affect hormonal dysregulation, metabolic diseases, and cancer.
Article
Biochemistry & Molecular Biology
Noah K. Babel, Brian J. Feldman
Summary: Our research identified a previously unrecognized ADAMTS1-PTN-Wnt pathway in regulating adipose precursor cell behavior. The non-muscle myosin protein MYH9 was found to be a key target of this pathway for modulating adipogenesis. These findings offer potential for developing novel therapeutics for obesity and related metabolic disorders.
Article
Biochemistry & Molecular Biology
Martiniano Bello
Summary: This study explores the structural and thermodynamic basis of molecular recognition between ERβ and DPN and its derivatives using molecular dynamics simulations and end-point methods. The results show that the MMGBSA approach is able to reproduce experimental trends and identify eight residues that strongly interact with the ligands.
